DQ2.5-glia-α1	TRAV	TRAJ	CDR3 a	TRBV	TRBJ	TRBD	CDR3 β
S2	4*01	4*01	CLVGDGGSFSGGYNKLIF	20-1*01	2-5*01	2*01	CSAGVGGQETQYF
L5107	24*01	53*01	CAFIGGSNYKLTF	20-1*01	2-2*01	1*01	CSAREPDNTGELFF
L6	21*01	57*01	CAVTLGGGSEKLVF	5-5*01	1-1*01	1*01	CASSFSPAGSEAFF
L10	8-3*01	44*01	CAVGWEDGTASKLTF	20-1*01	2-3*01	2*02	CSASRWRSTDTQYF
DQ2.5-glia-α2							
S16	26-1*01	32*01	CIVWGGATNKLIF	7-2*01	2-3*01		CASSVRSTDTQYF
D1	8-3*01	42*01	CAVGRGGSQGNLIF	4-2*01	2-1*01	1*01	CASSQYQSLVRGNNEQFF
101136	26-1*01	20*01	CIVHNDYKLSF	7-2*01	2-3*01	1*01	CASSIRSTDTQYF
L3-13	14/DV4*03	40*01	CAMSVLSGTYKYIF	4-1*01	2-5*01	1*01	CASSHVDRGGETQYF

Supplementary Table 1. HLA-DQ2.5-glia-a1/a2-specificT-cell clones and their TCR gene usage





Supplementary Figure 1. Effect of pH on transamidation and deamidation of DQ 2.5-glia-ala and DQ 2.5-glia- α 2 peptides. (A) Effect of pH on DQ 2.5-glia- α 1a reaction induced by mTG in presence of Lys. (B) Effect of pH on DQ 2.5-glia-ala reaction induced by mTG in presence of GEE. (C) Effect of pH on DQ 2.5-glia- α 1a reaction induced by mTG in presence of Lys. (D) Effect of pH on DQ 2.5glia- α 1a reaction induced by mTG without acyl-acceptor. (E) Effect of pH on DQ 2.5-glia- α 2 reaction induced by mTG in presence of Lys. (F) Effect of pH on DQ 2.5-glia- α 2 reaction induced by mTG in presence of GEE. (G) Effect of pH on DQ 2.5-glia- α 2 reaction induced by mTG in presence of Lys. (H) Effect of pH on DQ 2.5-glia- α 2 reaction induced by mTG without acyl-acceptor. All of presented molecular mass is monoisotopic mass. Peak area ratio in (D) and (H) is peak1: peak2 (peak1=(1) + (1) and peak 2=(2)+(2)). The deamidation of $Q \rightarrow E$ would be present a 1 Dalton shift, namely peak (1) shifted to peak (2). Regarding DQ 2.5-glia- α 1a peptide (supplementary Figure 1D), the area ratio between peak 1 (peak 1+ peak 1) and peak 2 (peak 2+ peak 2) was 1:5.18 (pH 6), whereas that was 1:2.28 (pH 7), 1:1.17 (pH 8) and 1:0.93 (native peptide). Simultaneously, for the DQ 2.5-glia-α2 peptide (supplementary Figure 1H), the area ratio between peak 1 and peak 2 increased in pace with the ascent of pH, which was 1:5.73 (pH 6), 1:1.63 (pH 7) and 1:1.2 (pH 8). The intensity ratio between peak 1 and peak 2 was similar to the area ration between them (data not shown).



b-HA	[M+H] ⁺	114.09	242.15	339.20	486.27	583.32	711.38	808.44	952.49	1065.57	1162.63	1325.69	1422.74	-
b-GEE	E [M+H]⁺	114.09	242.15	339.20	486.27	583.32	711.38	808.44	1022.53	1135.61	1232.67	1395.73	1492.78	-
b	[M+H]*	114.09	242.15	339.20	486.27	583.32	711.38	808.44	936.49	1049.58	1146.63	1309.69	1406.70	-
		1	2	3	4	5	6	7	8	9	10	11	12	13
		L	Q	Р	F	Р	Q	Р	Q	L	Р	Y	Р	Q
		13	12	11	10	9	8	7	6	5	4	3	2	1
у	[M+H]⁺	-	1439.73	1311.67	1214.62	1067.55	970.50	842.44	745.39	617.33	504.25	407.19	244.13	147.08
y-GEE	E [M+H]⁺	-	1525.77	1397.71	1300.66	1153.59	1056.54	928.48	831.42	617.33	504.25	407.19	244.13	147.08
y-HA	[M+H]⁺	=	1455.73	1327.67	1230.62	1083.55	986.49	858.44	761.38	617.33	504.25	407.19	244.13	147.08



Supplementary Figure 2. Identification of transamidated sites induced by mTG using LTQ-FT Ultra. (A) Observed fragment of DQ 2.5-glia-α1a before treatment (upper spectrum), after treatment with

1525.77 1378.70 1281.65 1153.59 1056.54 842.44

y-GEE [M+H]*

y-HA [M+H]*

-

632.30

469.24

372.19 244.13

147.08

729.36

1455.73 1308.66 1211.61 1083.55 986.49 842.44 729.36 632.30 469.24 372.19 244.13 147.08

mTG in presence of GEE (left lower spectrum) and HA (right lower spectrum); predicted fragment ion masses in the table. Ions illustrating transamidation of the Q at position 8. (B) Observed fragment of DQ 2.5-glia- α 2 before treatment (upper spectrum), after treatment with mTG in presence of GEE (left lower spectrum) and HA (right lower spectrum); predicted fragment ion masses in the table. Ions illustrating transamidation of the Q at position 6. All of presented molecular mass is accurate mass. Arrows indicate the Da shift due to transamidation.



Supplementary Figure 3. Identification of tTG-mediated deamidation of transamidated DQ2.5-glia- α 2 by MALDI-TOF. (A) Mass spectrum of treatment for 1 h at 37 °C. DQ2.5-glia- α 2 (upper panel), DQ2.5-glia- α 2 after mTG transamidation with Lys (mTG-Lys, middle panel, absence of tTG), and

after tTG treatment of Lys transamidated DQ2.5-glia- α 2 (tTG-mTG-Lys, lower panel, with tTG). (B) Mass spectrum of treatment for 2 h at 37 °C. (C) Mass spectrum of treatment for 4 h at 37 °C. (D) Mass spectrum of treatment for 8 h at 37 °C. (E) Mass spectrum of treatment for 16 h at 37 °C. Arrows indicate the Da shift.



Supplementary Figure 4. Transamidation of DQ2.5-glia- α 2 with LME and effect of tTG treatment of transamidated peptide. Mass spectrum of DQ2.5-glia- α 2 (upper panel), DQ2.5-glia- α 2 after mTG transamidation with LME (mTG-LME, middle panel), and after tTG treatment of LME transamidated DQ2.5-glia- α 2 (tTG-mTG-Lys, lower panel).



Supplementary Figure 5. Time-tracking of mTG transamidation by MALDI-TOF. (A) mTG mediated transamidation in presence of Lys at 5 min, 10 min, 20 min, 40 min, 1 h, 4 h and 24 h. (B) mTG mediated transamidation in presence of GEE at 5 min, 10 min, 20 min, 40 min, 1 h, 4 h and 24 h. All of presented molecular masses are accurate mass. Arrows indicate the Da shift due to transamidation.



Supplementary Figure 6. Transamidation of DQ2.5-glia- α 2 with BL and reactivity pattern of glia- α 2specific-T-cell clone to mTG-treated and tTG-mTG treated peptide. (A) Mass spectrum of DQ2.5glia- α 2 (upper panel), DQ2.5-glia- α 2 after mTG transamidation with BL (mTG-BL, middle panel), and after tTG treatment of BL transamidated DQ2.5-glia- α 2 (tTG-mTG-BL, lower panel). (B) Reactivity pattern of glia- α 2-specific T-cell clone S16 to DQ2.5-glia- α 2 (left panel), before (NC) and after mTG transamidation with BL (mTG-BL) and after tTG treatment of mTG-BL (tTG-mTG-BL). All of presented molecular mass is accurate mass. Arrows indicate the Da shift.